Acute Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Acute Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-05-06Clinical Trial Update: Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia [Phase 2]
Phase 2 clinical trial evaluating low-dose daunorubicin in pediatric relapsed/refractory acute leukemia has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2023-04-27Clinical Trial Update: Reduced Intensity Conditioning Transplant Using Haploidentical Donors [Phase 2]
Phase 2 clinical trial investigating reduced intensity conditioning transplant using haploidentical donors for various hematologic malignanc…
-
CLINICAL_TRIALS trial_result · 2023-04-26Clinical Trial Update: Guadecitabine Extension Study [Phase 2]
Phase 2 extension study of guadecitabine in acute myeloid leukemia and myelodysplastic syndrome was terminated; results were posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-04-21Clinical Trial Update: Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT [Phase 2]
A Phase 2 clinical trial evaluating a conditioning regimen combining venetoclax, azacytidine, and a modified BUCY approach for patients with…
-
EMA approval · 2023-04-19EMA Authorised: Ceplene (histamine dihydrochloride) — Laboratoires Delbert
Authorised status for Ceplene (histamine dihydrochloride) for acute myeloid leukemia/therapy by Laboratoires Delbert in the EU.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-04-18Clinical Trial Update: Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia [Phase 1, Phase 2]
Phase 1/2 trial assessing safety and efficacy of a CD123-targeted CAR-T therapy for relapsed/refractory acute myeloid leukemia.
-
CLINICAL_TRIALS trial_result · 2023-04-18Clinical Trial Update: MG4101 for Refractory or Relapsed AML [Phase 2]
Phase 2 clinical trial update for MG4101 in refractory or relapsed acute myeloid leukemia has completed.
-
CLINICAL_TRIALS trial_result · 2023-04-18Clinical Trial Update: CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia [Phase 1, Phase 2]
Phase 1/2 clinical trial update on a CD123-targeted CAR-T cell therapy for relapsed/refractory acute myeloid leukemia.
-
CLINICAL_TRIALS trial_result · 2023-04-12Clinical Trial Update: Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies [Phase 1]
Phase 1 trial updating safety, tolerability, pharmacokinetics, and efficacy of AMG 397 in relapsed or refractory hematological malignancies;…
-
CLINICAL_TRIALS trial_result · 2023-04-11Clinical Trial Update: Venetoclax Combined With Azacitidine and CAG in Refractory/Relapse Acute Myeloid Leukemia [Phase 2]
Phase 2 trial evaluating venetoclax with azacitidine and CAG regimen in refractory/relapsed acute myeloid leukemia.
-
CLINICAL_TRIALS trial_result · 2023-04-11Clinical Trial Update: Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia [Phase 1, Phase 2]
A Phase 1/2 study evaluating intensity-modulated radiation therapy with etoposide and cyclophosphamide followed by donor stem cell transplan…
-
CLINICAL_TRIALS trial_result · 2023-04-07Clinical Trial Update: Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML [Phase 2, Phase 3]
Phase 2/3 trial evaluating venetoclax with homoharringtonine and cytarabine for induction in acute myeloid leukemia, currently recruiting.
-
CLINICAL_TRIALS trial_result · 2023-04-04Clinical Trial Update: Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia [Phase 2]
Phase 2 trial evaluating Clofarabine plus Melphalan as a conditioning regimen before donor stem cell transplantation for patients with myelo…
-
CLINICAL_TRIALS trial_result · 2023-04-04Clinical Trial Update: A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML [Phase 1, Phase 2]
A Phase I/II dose-escalation and expansion study evaluating BST-236 combined with venetoclax in adults with unfit newly diagnosed acute myel…
-
FDA approval · 2023-03-27FDA Approved: DAURISMO — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for DAURISMO (glasdegib) submitted by Pfizer Laboratories Div Pfizer Inc. The action relates to …
-
CLINICAL_TRIALS trial_result · 2023-03-27Clinical Trial Update: TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib [Phase 2]
Phase 2 clinical trial update evaluating bortezomib to overcome epigenetic therapy resistance in acute myeloid leukemia has completed.
-
CLINICAL_TRIALS trial_result · 2023-03-23Clinical Trial Update: Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation [Phase 3]
This clinical trial update reports results from a Phase 3 study of ivosidenib combined with azacitidine versus placebo in previously untreat…
-
CLINICAL_TRIALS trial_result · 2023-03-23Clinical Trial Update: Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation [Phase 3]
Phase 3 trial evaluating AG-120 (ivosidenib) plus azacitidine vs placebo in previously untreated IDH1-mutated acute myeloid leukemia.
-
CLINICAL_TRIALS trial_result · 2023-03-21Clinical Trial Update: Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R [Phase 2]
Phase 2 trial evaluating autologous bone marrow transplantation using a preparative regimen of busulfan/fractionated total body irradiation …
-
CLINICAL_TRIALS trial_result · 2023-03-20Clinical Trial Update: A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy [Phase 3]
Phase 3 trial evaluating venetoclax with azacitidine or decitabine in outpatient AML patients ineligible for intensive chemotherapy has comp…
-
CLINICAL_TRIALS trial_result · 2023-03-15Clinical Trial Update: A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS [Phase 1, Phase 2]
Clinical trial update for 6MW3211 in AML and MDS across Phase 1 and Phase 2
-
CLINICAL_TRIALS trial_result · 2023-03-10Clinical Trial Update: Busulfan (BU) Plus Fludarabine Vs Intravenous BU Plus Cyclophosphamide as Conditioning Regimens Prior Allogeneic Hematopoetic Stem Cells Transplant (HSCT) in AML [Phase 3]
A Phase 3 trial comparing busulfan plus fludarabine versus intravenous busulfan plus cyclophosphamide as conditioning regimens before alloge…
-
CLINICAL_TRIALS trial_result · 2023-03-10Clinical Trial Update: Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant [Phase 2, Phase 3]
A Phase 2/3 clinical trial comparing thymoglobulin to alemtuzumab in patients undergoing allogeneic stem cell transplantation has been compl…
-
CLINICAL_TRIALS trial_result · 2023-03-10Clinical Trial Update: Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML) [Phase 2]
Phase 2 trial evaluating imatinib in relapsed/refractory acute myeloid leukemia.
-
CLINICAL_TRIALS trial_result · 2023-03-09Clinical Trial Update: Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia [Phase 3]
Phase 3 trial evaluating induction therapy with Clofarabine or Daunorubicin hydrochloride plus Cytarabine, followed by Decitabine or observa…